CliffBio
small molecule

EXFORGE

AMLODIPINE BESYLATE; VALSARTAN

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameEXFORGE
Active ingredientAMLODIPINE BESYLATE; VALSARTAN
StrengthEQ 10MG BASE;160MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2007
Marketing statusRX

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.